Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03535870 · ClinicalTrials.gov registry record · NA
Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)
A NA study, sponsored by West-Ward Pharmaceutical.
- Completed
- Registry status
- NA
- Development phase
- 1,556
- Enrollment target
NCT03535870 is a NA study that has completed, run by West-Ward Pharmaceutical. The registered enrollment target is 1,556 participants.
The verdict
NCT03535870, a NA study, has completed, sponsored by West-Ward Pharmaceutical.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,556 participants
- Enrollment target
Study Summary
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
Interventions
- DRUG Placebo
- DRUG Fluticasone propionate/salmeterol
- DRUG Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,556 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2019-09-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03535870
The ClinicalTrials.gov registry entry for NCT03535870 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,556 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West-Ward Pharmaceutical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03535870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03535870 about?
NCT03535870 is a clinical study titled "Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)". A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
What is the current status of trial NCT03535870?
This trial is currently completed. It is a NA study. The enrollment target is 1,556 participants. The study started on 2018-04-26. Estimated completion is 2019-09-10.
What interventions are being tested in trial NCT03535870?
The interventions under investigation include: Placebo (DRUG), Fluticasone propionate/salmeterol (DRUG), Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT03535870?
This trial is sponsored by West-Ward Pharmaceutical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.